Event in Progress:
Discover the latest content that has just been published on Research Tree
CureVac reported a broadly unchanged pre-tax loss, which came from higher revenues from the GSK cooperation (milestone payment) as the R&D costs increased driven by the intensified activities in infectious diseases and oncology. The infringement ruling points to a positive outcome and the RNA Printer® has received a manufacturing license for GMP-grade manufacturing. The Q3 figures came in short of our expectations.
Companies: CureVac N.V.
AlphaValue
CureVac’s Q2 report was far from being an event. The management failed to step up the dialogue with investors and missed an opportunity to update the development strategy and the pipeline. Owing to the company’s limited funding, we continue to anticipate a streamlining of the R&D pipeline so as to focus on the most promising candidates. The company reported the expected pattern of figures with an EBIT loss above our expectations.
CureVac’s preliminary figures are now like those of a start-up, showing low revenues and big (operating) losses. As a kind of farewell gift the former CEO, Mr Haas, filled CureVac’s money box with increased cash at hand. The ongoing patent litigation and counterclaims between BioNTech/Pfizer and CureVac are now coming to the forefront. CureVac seems to be seeking a financial settlement (cash, royalties etc) and not a production stop for COVID-19 vaccines or boosters. The figures were below o
The question remains should we or should we not see 2022 as a transition year? The new CEO, Mr Zehnder, has taken a small step in the right direction by postponing the beginning of a clinical trial. But much more is needed as the current cash reserves are finite. The FY figures did not meet our expectations, except for cash reserves at the year-end.
CureVac NV (CureVac) is a pioneer in the discovery of natural mRNA as a generator of an immune response. This new drug class was a game changer in the fight against COVID-19 via the rapid and successful development of protective vaccines. Unfortunately, CureVac came late to this party at a time when the COVID-19 bonanza had already been shared between faster, successful vaccine developers. On the other hand, the firm managed to raise new funding while governments were throwing money at companies
Research Tree provides access to ongoing research coverage, media content and regulatory news on CureVac N.V.. We currently have 0 research reports from 1 professional analysts.
Share: